NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2022 – November 30, 2022 The report is available on the company’s website:
https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker “NXTCL”. The amount in brackets refers to the corresponding period in the previous year.
● At the end of October, NextCell’s CEO, Mathias Svahn, presented an update on the Company’s achieved and ongoing clinical operations with the drug candidate ProTrans, which has been developed for type-1 diabetes, and other autoimmune and inflammatory diseases.
● NextCell announced in mid-December that the first two adolescents in the older age cohort (12-21 years) had undergone treatment in phase II part of the paediatric diabetes study.
● The company announced in mid-January that it had received positive comments and recommendations on the proposal for paediatric plan (PIP) previously submitted to the Paediatric Unit of the European Medicines Agency (PDCO)
● NextCell announced at the end of January that it is expanding the ProTrans study in COVID-19 to the treatment of severe pneumonia caused by influenza, RS and HMP viruses.
This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 26-01-2023 07:30 CET.
For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 5595
E-mail: info@nextcellpharma.com
Website:
NextCell Pharma AB: www.nextcellpharma.com
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser, 08-528 00 399, info@fnca.se.
About NextCell Pharma ABNextCell is a cell therapy company in clinical phase II. The company has developed a proprietary and patented platform technology to produce mesenchymal stromal cells adapted for allogeneic treatment of various autoimmune and immunological diseases. The drug candidate ProTrans is now being tested for the treatment of type-1 diabetes as well as respiratory complications caused by Sars-CoV-2 infection. The focus is to take ProTrans to market approval for type-1 diabetes via a phase III study. ProTrans is evaluated in two clinical COVID-19 studies, in Sweden and Canada. NextCell is working on completing its own GMP facility for the manufacture of ProTrans. The GMP facility is expected to be ready for manufacturing smaller quantities of ProTrans in 2023. NextCell also owns 8.5% of FamicordTX, a start-up company in CAR-T and oncology, and 100% of Cellaviva, Scandinavia’s largest stem cell bank for family savings of stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).
https://news.cision.com/nextcell-pharma-ab/r/nextcell-publishes-its-interim-report-1-2022-2023,c3703224
https://mb.cision.com/Main/15834/3703224/1804570.pdf
(c) 2023 Cision. All rights reserved., source Press Releases – English